Top Ten Biotech Stocks Right Now: $AGIO, $MIRM, $COGT, $GRAL

Reference: October 20, 2026 regular-session close, 4 p.m. EDT. $36.64. Indicative market cap about 2.19B USD at that close, based on the share count used by Finviz. Dated market observations, not live quotes.

Why it ranks first: Agios combines a clearly dated regulatory decision with an operating business that can absorb either outcome. The November 1 action date covers the supplemental application for mitapivat in sickle cell disease, potentially the drug’s largest indication. Unlike a single-asset pre-commercial company, Agios already sells mitapivat in pyruvate kinase deficiency and thalassemia, reported $44.7 million of worldwide product revenue in the second quarter, and ended June with $964.8 million in cash, equivalents and marketable securities. Q2 GAAP net loss was $100.7 million; the cash balance is a dated measure, not a guarantee against future financing needs. The July 30 financial report remains the dated source for these balances; the November 1 target is a regulatory goal, not a guaranteed outcome.

The evidence package is genuinely mixed rather than simply “positive.” In RISE UP, 40.6% of mitapivat-treated patients achieved the prespecified hemoglobin response versus 2.9% on placebo. However, the co-primary endpoint measuring annualized sickle-cell pain crises did not reach statistical significance, and the key fatigue endpoint was also missed. Agios therefore filed through the accelerated-approval pathway around the anti-hemolytic effect, while the REIGNITE Phase 3 confirmatory trial is designed to test clinical benefit through transfusion-related outcomes.

The key question is not whether mitapivat changes red-cell biology—it clearly does—but whether FDA accepts that hematologic effect as sufficiently likely to predict benefit in this population. Label breadth, post-marketing commitments and risk-management language could matter almost as much as the binary headline.

Merlintrader view: $AGIO leads this editorial research ranking because the potential new indication is material while existing products and reported liquidity provide resources beyond this single decision. Approval, label breadth and commercial uptake remain uncertain.

Reference: October 20, 2026 regular-session close, 4 p.m. EDT. $85.07. Indicative market cap about 5.52B USD at that close, based on the share count used by Finviz. Dated market observations, not live quotes.

AZURE-1 result, September 28: brelovitug met the Phase 3 primary endpoint in chronic hepatitis delta at both doses. The study randomized 153 treatment-naive patients 2:2:1 to 300 mg weekly (n=59), 900 mg every four weeks (n=65) or delayed treatment starting at week 24 (n=29). The week-24 combined endpoint of virologic response plus ALT normalization was reached by 56% and 45% of patients on the two doses versus 0% with delayed treatment (p<0.0001 for both). Virologic response was 86% and 85%, ALT normalization 63% and 54%, and HDV RNA below the 10 IU/mL quantification limit 25% and 26%. Through week 24 there were no grade 3 or higher adverse events in the brelovitug arms and no treatment-related discontinuations; injection-site reactions occurred in 10.2% and 18.5% of patients.

How to read AZURE-1: the control arm was delayed treatment, not an approved active therapy, so the result shows activity against no treatment over 24 weeks rather than superiority over another drug. Separate Phase 2b follow-up (20 patients per arm) showed the combined response rising to 55% in both arms at week 48; those are smaller, earlier-phase data and should not be pooled with the Phase 3 comparison. AZURE-4, the second pivotal study, is guided to report topline in Q4 2026; Mirum plans a BLA in the first half of 2027 and a potential U.S. launch in Q4 2027. Atebrioz approval does not validate this separate program, and positive topline data are not an FDA decision.

What changed: Mirum and Incyte announced Atebrioz (zilurgisertib) approval on September 25, and FDA confirms the indication: reduction in the volume of total new heterotopic ossification in adults and pediatric patients aged 12 and older with fibrodysplasia ossificans progressiva. The old September 26 PDUFA target is therefore resolved. On October 12 Mirum also reported that the Phase 3 EXPAND study of LIVMARLI (maralixibat) met its primary endpoint in a study that enrolled 52 patients (46 pediatric) with ultra-rare cholestatic liver diseases, including biliary atresia: the itch score improved 1.81 points versus 0.83 on placebo (p=0.0004), serum bile acids fell 70.1% versus 3.5% (p<0.0001) and all five prespecified secondary endpoints were statistically significant; diarrhea occurred in 64.0% versus 11.1% of patients. Mirum plans an sNDA in the first half of 2027. A price change does not isolate the market’s assessment of any single program. Mirum 8-K · October 12

Why it remains in the research queue: the question has shifted from whether the application clears review to how a newly approved medicine fits into a very small, competitive market. Approval supplies a defined label; it does not establish reimbursement, prescribing penetration, adherence or eventual peak sales. Mirum already has a rare-disease commercial platform, but successful execution in one disease does not guarantee the same pace in another.

How to read the evidence after approval: PROGRESS randomized 32 patients to zilurgisertib and 31 to placebo. The original prespecified new-lesion incidence comparison was 1 versus 5 patients at week 24, with p=0.0986. That historical result remains relevant. FDA’s approval summary instead describes the efficacy basis in terms of the change in total new heterotopic-ossification volume: an average 3.2 cm³ decrease with Atebrioz versus a 24.6 cm³ increase with placebo. The volume measure and the count of patients with new lesions are different endpoints. Approval does not retroactively turn the incidence test into a statistically significant result, nor does a volume endpoint establish reversal of existing disability.

Safety and positioning: FDA highlights embryo-fetal risk, relevant drug interactions and adverse reactions including headache, joint pain, upper respiratory infection, nosebleeds and nausea. These considerations can affect patient selection and treatment persistence. FDA describes Atebrioz as the third approved FOP treatment, so comparisons must focus on approved population, endpoint, safety and practical use. No head-to-head superiority claim follows from comparing separate pivotal studies.

Financial capacity: Q2 net product sales were $176.2 million and management’s reported 2026 guidance was $680–700 million. Cash and investments were $561.3 million at June 30, with a Q2 GAAP net loss of $67.2 million. Financing included $690 million of 0% convertible notes due 2032 and retirement of $237.2 million principal of older notes. Those dated balances are not a post-approval cash update, and liquidity is not synonymous with net cash. The Incyte license also carries milestone and royalty obligations; new product sales do not all flow through to common shareholders.

What needs to be demonstrated next: an accessible treatment pathway, practical payer coverage, initial prescribing and a clear account of launch spending. The September 25 joint company release expects U.S. commercial availability in October through Mirum Access Plus. October is a launch window, not a specific day; neither a specific launch day nor any new revenue contribution is built into this outlook. The next financial update should show how launch costs, debt and existing-product growth interact, rather than treating FDA approval as a complete financial thesis.

Merlintrader view: Mirum retains second place. The Atebrioz decision, the AZURE-1 readout and the EXPAND readout are resolved favorably; the open questions are launch execution, AZURE-4 confirmation and the 2027 brelovitug filing. Assess them alongside access, launch costs, convertible debt and license economics.

Reference: October 20, 2026 regular-session close, 4 p.m. EDT. $31.24. Indicative market cap about 5.42B USD at that close, based on the share count used by Finviz. Dated market observations, not live quotes.

Why it ranks third: Cogent has the densest regulatory sequence in the ranking. FDA is reviewing bezuclastinib plus sunitinib in post-imatinib GIST for November 30, single-agent bezuclastinib in nonadvanced systemic mastocytosis for December 30, and a third application in advanced systemic mastocytosis for June 29, 2027.

The GIST package is especially strong on paper. In the randomized Phase 3 PEAK trial, median progression-free survival was 16.5 months with the combination versus 9.2 months with sunitinib alone, hazard ratio 0.50. Objective response was 46% versus 26%, while overall-survival data remained immature. FDA granted Priority Review and the program also carries Breakthrough Therapy and Real-Time Oncology Review designations; the company has said no AdCom is currently planned and no filing-review issue was identified at acceptance.

Cogent reported $792.3 million of cash and securities at June 30 and $73.6 million gross ATM proceeds after quarter-end, disclosed August 10. Their $865.9 million sum is illustrative pro forma before fees and subsequent spending, not reported current cash; net ATM proceeds were $71.4 million. On August 10 Cogent also filed a new at-the-market prospectus for up to $400 million, which is capacity for future share sales rather than cash raised. The nonadvanced systemic mastocytosis PDUFA is December 30; the AdvSM application accepted September 15 has a June 29, 2027 target.

Merlintrader view: Cogent holds third. Both November 30 and December 30 lie within the watch window through January 21. Randomized evidence and reported resources support its priority; competition, label risk and launch spending remain unresolved.

Reference: October 20, 2026 regular-session close, 4 p.m. EDT. $124.67. Indicative market cap about 5.57B USD at that close, based on the share count used by Finviz. Dated market observations, not live quotes.

Why it ranks fourth: the September 23 advisory meeting has taken place. GRAIL reported that seven panelists voted that Galleri’s benefits outweigh its risks, two voted no and one abstained; safety voting was 10–0 and effectiveness 6–4. The recommendation is nonbinding. GRAIL expects an FDA PMA decision in the coming months, but no fixed action date has been announced. The ranking now reflects the unresolved review and clinical-utility debate rather than an upcoming panel.

The evidence cannot be summarized honestly with a single positive or negative label. GRAIL reported that NHS-Galleri did not significantly reduce the combined incidence of stage III and IV cancers, the study’s central late-stage measure. The company also reported a 22% and 26% reduction in stage IV diagnoses across 12 prespecified aggressive cancers in screening rounds two and three, more early-stage screen-detected cancers, and fewer emergency presentations. PATHFINDER2 and a large intervention arm support feasibility, cancer-signal origin and diagnostic-resolution questions, but they do not eliminate uncertainty about mortality, overdiagnosis and downstream procedures.

GRAIL generated $44.7 million of total Q2 revenue, $42.6 million of it from Galleri, and ended June with $861.6 million of liquidity, giving it room to survive a slower path. Galleri remains central to the corporate thesis. The favorable vote supports the regulatory narrative, while the split effectiveness vote underlines remaining disagreement; FDA approval and payer coverage remain separate unresolved hurdles.

FDA panel qualifications: the official meeting summary records doubts about a broad early-detection claim and describes favorable votes tied to appropriate labeling, further studies and clinician/patient education. Galleri should complement established screening. A positive test does not confirm cancer and a negative test does not exclude it; the long-term effect on patient outcomes remains unestablished. These qualifications matter when interpreting the headline vote.

October 21 review: no new GRAIL release or FDA action on Galleri was found between October 17 and 21. A Form 4 filed October 16 reports that chief executive Joshua Ofman sold 20,000 shares on October 15 under a Rule 10b5-1 trading plan; a pre-arranged plan sale is not a statement about the review. The shares closed at $124.67 on October 20. The October 5 company release schedules NHS-Galleri and PATHFINDER 2 presentations at ESMO on October 25 and 26. These are scientific presentations, not a dated FDA action. The release states Galleri is not FDA cleared or approved.

Merlintrader view: $GRAL remains a high-priority research case after the advisory vote, with final FDA review still pending. The missed NHS-Galleri late-stage objective and unresolved mortality benefit remain central even after a favorable recommendation.

Reference: October 20, 2026 regular-session close, 4 p.m. EDT. $92.97. Indicative market cap about 5.84B USD at that close, based on the share count used by Finviz. Dated market observations, not live quotes.

Why it ranks fifth: DAYBREAK has moved from an upcoming binary readout to a reported positive Phase 3 result. In its September 28, 2026 release at 6:30 a.m. EDT, Kodiak said both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) met their year-one visual-acuity non-inferiority primary endpoints versus aflibercept in wet AMD. The reported p-values were 0.0007 and 0.0036, respectively. These are non-inferiority findings, not proof of superiority in vision.

Zenkuda: durability alongside vision preservation. The sponsor reported 54% of patients on a 24-week dosing interval at year one under strict treat-to-dryness retreatment criteria. Following four monthly loading doses, individualized dosing ranged from four to 24 weeks. Intraocular inflammation was 0% and cataract adverse events 0.5%, versus 0.9% cataract events with aflibercept. A majority reaching six-month intervals is clinically relevant, but does not imply that every patient can use that interval.

KSI-501 is a separate read. Tabirafusp-ted also met its anatomical key secondary endpoint (p<0.0001). Intraocular inflammation was 0.4% and cataract adverse events 0%. Its regimen was every eight weeks after loading, with additional individualized dosing up to monthly; the Zenkuda 54% durability figure does not apply to this arm. Planned post-hoc subgroup work is exploratory. The ongoing ALTO Phase 3 study tests the potential for superiority in diabetic macular edema; DAYBREAK does not establish that future result.

What comes next: after the AAO 2026 presentations of October 9–10 (DAYBREAK, APEX and GLOW2, as set out in the company’s October 7 release), Kodiak plans a multi-indication Zenkuda BLA submission in Q4 2026, supported by five positive Phase 3 studies across wet AMD, diabetic retinopathy and retinal vein occlusion. KSI-101 PEAK Pivotal Analysis 1 remains guided to December 2026; the company also plans a KSI-101 BLA in Q2 2027. These are company windows, not exact dates or FDA approvals.

Kodiak ended Q2 with $125.9 million in cash, reported a $65.6 million quarterly net loss and guided resources into 2027. Those are June 30 financial figures and the previously disclosed runway, not a new cash balance. Positive clinical data can strengthen a regulatory package, but do not themselves fund submission preparation, further trials or commercialization. Financing and execution remain material risks.

Ownership filing, September 30: Baker Bros. affiliated funds reported purchases of 1,941,755 Kodiak shares on September 28–29, for approximately $157.0 million at an average of about $80.85 per share. The filing describes over-the-counter transactions directly with a broker-dealer and reports 35.0% beneficial ownership including options. This is a dated ownership disclosure, not company funding or an updated cash balance; the holding does not establish clinical or regulatory success.

Financing capacity, October 20: Kodiak filed an automatic shelf registration (Form S-3ASR) that includes a prospectus for an at-the-market program of up to $350 million through J.P. Morgan Securities, under a distribution agreement dated October 20, for general corporate purposes. This is capacity to sell shares over time, not cash raised; any sales would increase the share count (Form S-3ASR · October 20).

Reading the evidence: these are sponsor-reported topline findings. The release does not provide a complete arm-level numerical visual-acuity table and confidence intervals. Detailed analyses, missing-data handling, injection burden and longer follow-up remain relevant to judging competitive differentiation and benefit-risk. Neither clinical success nor a planned BLA is FDA acceptance or marketing authorization.

Merlintrader view: DAYBREAK is now a completed clinical catalyst. The research focus shifts to the quality of the full dataset, Zenkuda filing execution, financing and the distinct December PEAK readout. The research ranking is retained; it is not a buy or sell recommendation.

Reference: October 20, 2026 regular-session close, 4 p.m. EDT. $264.49. Indicative market cap about 7.38B USD at that close, based on the share count used by Finviz. Dated market observations, not live quotes.

Why it ranks sixth: relutrigine’s December 27 target falls inside the October 21–January 21 core window. FDA extended the previous September 27 date after additional analyses were classified as a major amendment. The June extension disclosure reported no request for a new trial and no safety or manufacturing concern. Separately, the August 6 mid-cycle update reported no major safety or efficacy concern and no planned AdCom; these are company reports about the ongoing review, not a final FDA conclusion.

The application targets SCN2A- and SCN8A-related developmental and epileptic encephalopathies, severe pediatric conditions with no specifically approved treatment. EMBOLD produced marked reductions in motor seizures and seizure freedom in some heavily pretreated patients, but the rarity of the disorders and the development program’s design mean FDA must judge a relatively small evidence package. Sensitivity analyses matter most when results can change under assumptions about baseline, missing data, external comparisons or patient heterogeneity.

Praxis ended Q2 with approximately $1.4 billion in cash and investments and guided runway into 2028. It also has several late-stage CNS programs, so relutrigine is strategically important without being the only source of enterprise value. The broader relutrigine EMERALD Phase 3 readout is guided to Q4 2026 and is distinct from the pending SCN2A/SCN8A application. Pipeline breadth is not proof of success: vormatrigine’s POWER1 study missed its primary endpoint, as summarized in the August corporate update. A second application, ulixacaltamide in essential tremor, carries a January 29, 2027 PDUFA date, beyond the core window. Praxis has said it does not intend to communicate regulatory updates until the PDUFA dates; that communication policy does not establish the outcome of either review.

Merlintrader view: $PRAX stays in the Top Ten because the event is material and the company is unusually well funded. Its December 27 target is now inside the core horizon; the retained research order also weighs evidence quality, review uncertainty and financial resilience.

Reference: October 20, 2026 regular-session close, 4 p.m. EDT. $4.76. Indicative market cap about 977.99M USD at that close, based on the share count used by Finviz. Dated market observations, not live quotes.

Why it ranks seventh: MOLBREEVI has a precise November 22 target date in autoimmune pulmonary alveolar proteinosis. FDA extended the review after classifying Savara’s responses to information requests as a major amendment. Savara said the extension communication did not identify safety, efficacy or manufacturing concerns, an important distinction from a review that has already exposed a substantive deficiency.

The clinical thesis is straightforward: inhaled molgramostim is intended to restore GM-CSF signaling in alveolar macrophages so they can clear accumulated surfactant. Savara has reported sustained long-term improvements in lung function and respiratory health-related quality of life. New IMPALA analyses and long-term IMPALA-2 data were scheduled for CHEST 2026 on October 20–21 (Savara release, October 12); no post-presentation company release had been issued by October 21. Because autoimmune PAP is rare and specialist-managed, a concentrated commercial model is plausible, but the company has no marketed product and essentially all near-term equity value remains tied to MOLBREEVI.

At June 30 Savara held approximately $173 million in cash and short-term investments and $30.1 million of debt; Q2 net loss was $40.2 million. Up to $75 million of additional debt and $75 million under a royalty arrangement are conditional on FDA approval. These are financing facilities with repayment or royalty costs, not free cash or protection against rejection.

Merlintrader view: Savara stays seventh on its defined date and clinical package. First-product concentration and approval-dependent capital keep the risk high.

Reference: October 20, 2026 regular-session close, 4 p.m. EDT. $6.61. Indicative market cap about 384.30M USD at that close, based on the share count used by Finviz. Dated market observations, not live quotes.

Why it stays at eight: the October 5 HOPE-3 extension update remains the latest clinical update ahead of the November 22 review; no new company release followed between October 5 and 21. Capricor holds eighth because this is a defined small-cap research case with reported liquidity, while the regulatory disagreement prevents a higher position.

The July 29 advisory committee voted 3–9 against substantial evidence of effectiveness for cardiomyopathy in DMD. That was not a vote on the upper-limb primary endpoint. The nonbinding vote remains an adverse regulatory signal; a revised proposed upper-limb indication does not erase it.

The October 5 report describes a 76% slowing of upper-limb decline after placebo patients crossed to treatment, compared with their own preceding year. This is open-label evidence, not a second randomized comparison. No alpha was allocated to these analyses and the extension was not powered for month-24 comparisons.

Cash and marketable securities were $237.9 million on June 30; Q2 net loss was $40.7 million. The August 13 report guided funding for at least the next twelve months under its operating plan. This is dated guidance, not a current cash balance or a guarantee that launch spending will avoid dilution.

The August 24 amendment refined the proposed indication toward upper-limb function and extended the target to November 22. Approval, final labeling, manufacturing execution and the distribution dispute remain separate issues. The commercial read-through should not borrow efficacy claims from other DMD modalities.

Merlintrader view: the new data justify close research attention, not an assumption of approval. Read the randomized period, the uncontrolled extension and the July vote separately. Its eighth-place position reflects this tension.

Reference: October 20, 2026 regular-session close, 4 p.m. EDT. $5.15. Indicative market cap about 104.60M USD at that close, based on the share count used by Finviz. Dated market observations, not live quotes.

Why it remains in the Top Ten: SHIELD II met its primary composite endpoint (SSI, mortality or reintervention) and key secondary efficacy endpoints. The later company-reported 60% relative SSI reduction, p=0.0013, refers to the SSI endpoint, not to a 60% reduction in the composite. FDA accepted the NDA for Priority Review with a November 28 target and no filing-review issue identified at acceptance.

The June 30 cash balance of $6.6 million excludes the subsequent Azurity agreement for the United States and Canada. PolyPid said FDA acceptance satisfied all conditions for the $30 million upfront and near-term payments. The agreement provides up to approximately $320 million in total potential payments, plus tiered royalties from the mid-teens to mid-twenties. Remaining development, regulatory and sales milestones are conditional; the headline total is not cash on hand.

Manufacturing, labeling, safety and hospital adoption remain material uncertainties. Management’s runway forecast into 2028 depends on the agreement and expected future proceeds; it is not a forecast funded solely by the $6.6 million June cash balance. A signed partner does not guarantee approval or commercial uptake.

October 1 updates: EMA validated the D-PLEX100 marketing authorization application submitted September 14, starting the formal European review, and PolyPid regained European commercialization rights after its 2022 agreement with ADVANZ PHARMA was terminated by mutual agreement; no financial terms were disclosed. The release repeats the November 28 U.S. PDUFA date. Recovering European rights adds optionality, but also leaves PolyPid to find a new route to market there. On October 15 PolyPid scheduled a virtual Investor Day for October 28 at 11:30 a.m. ET, where it plans to introduce PD01B for diabetic foot infections; the release repeats the November 28 PDUFA date (PolyPid release).

Merlintrader view: PolyPid stays ninth. Pivotal data and the Azurity agreement support research attention; microcap scale, conditional capital and hospital execution limit its priority.

Reference: October 20, 2026 regular-session close, 4 p.m. EDT. $1.01. Indicative market cap about 104.44M USD at that close, based on the share count used by Finviz. Dated market observations, not live quotes.

Why it stays at ten: INO-3107 has an October 30 FDA target and a mechanism distinct from surgery for recurrent respiratory papillomatosis. A small market capitalization makes the event material, but limited financial resources and the evidence package put it at the bottom of the research ranking.

The published Phase 1/2 study is single-arm, with surgery burden compared with the pretreatment period. A reduction in procedures is clinically relevant but does not supply a randomized active-comparator estimate. Patient selection, natural fluctuation and the approval standard remain central questions.

The August 12 update says FDA review continues toward October 30 and discusses accelerated-approval eligibility and the confirmatory-trial design. Acceptance of an application does not guarantee that the proposed pathway or evidence will satisfy FDA. On October 20 INOVIO announced a favorable judgment of $80,416,101 in its litigation with VGXI and GeneOne Life Science in the Court of Common Pleas of Montgomery County, Pennsylvania: $61,750,789 in compensatory damages and $18,665,312 in attorneys’ fees and costs, and judgment was also entered against the defendants on their counterclaims. INOVIO itself warns that the defendants’ financial condition will likely impair collection of some or all of the award and that the judgment may be appealed, so it is not cash or runway (INOVIO release, October 20). The release does not change the October 30 review date. The shares closed at $1.01 on October 20.

June 30 cash, equivalents and short-term investments were $36.7 million. The July offering added approximately $18.3 million net. These dates are separate; adding the two without subsequent spending does not produce current cash.

Management guided runway into late Q1 2027, including the July raise, and estimated Q3 operating cash burn of about $18 million. That forecast leaves substantial financing and execution risk around a possible launch. The Q2 net loss benefited from a noncash warrant revaluation, so accounting loss is not a cash-burn proxy.

A fair competitive comparison looks separately at procedure reduction, durability, administration and the population actually studied. Cross-trial comparisons cannot establish superiority over another RRP treatment. A regulatory approval would still leave payer access and adoption to demonstrate.

Merlintrader view: included as an explicitly speculative microcap exception, not as an equal-risk substitute for Agios. The near-term FDA date merits monitoring; funding and uncontrolled evidence sharply limit the rank.